Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2) (FFAADA)
Hypertension, Diabetes

About this trial
This is an interventional prevention trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Males or females
- Obese subjects (body mass index (BMI) ≥ 30 kg/m^2)
- 18 and 65 years
- Blood pressure reading < 140/80 mm Hg and no prior history of hypertension
Exclusion Criteria:
- History of diabetes mellitus
- History of hypertension
- Fasting triglyceride levels > 250 mg/dL
- Liver disease (ALT 2.5x > upper limit of normal)
- Serum creatinine ≥1.5 mg/dL
- Smokers, drug or alcohol abuse
- Mental condition rendering the subject unable to understand the scope and possible consequences of the study
- Female subjects who are pregnant or breast feeding
Sites / Locations
- Grady Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Salsalate
Carvedilol
Placebo
Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.